Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response

被引:71
|
作者
von Locquenghien, Michelle [1 ]
Rozalen, Catalina [1 ]
Celia-Terrassa, Toni [1 ]
机构
[1] IMIM Hosp Mar Med Res Inst, Canc Res Program, Barcelona, Spain
来源
JOURNAL OF CLINICAL INVESTIGATION | 2021年 / 131卷 / 01期
关键词
EPITHELIAL-MESENCHYMAL TRANSITION; TOLL-LIKE RECEPTORS; IFN-GAMMA; TUMOR-CELLS; DOWN-REGULATION; IMMUNE CHECKPOINTS; BONE METASTASIS; STEM-CELLS; E-CADHERIN; T-CELLS;
D O I
10.1172/JCI143296
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Interferons (IFNs) are pleiotropic cytokines critical for regulation of epithelial cell functions and for immune system regulation. In cancer, IFNs contribute to tumor-intrinsic and-extrinsic mechanisms that determine the quality of antitumor immunity and response to immunotherapy. In this Review, we focus on the different types of tumor IFN sensitivity that determine dynamic tumor-immune interactions and their coevolution during cancer progression and metastasis. We extend the discussion to new evidence supporting immunotherapy-mediated immunoediting and the dual opposing roles of IFNs that lead to immune checkpoint blockade response or resistance. Understanding the intricate dynamic responses to IFN will lead to novel immunotherapeutic strategies to circumvent protumorigenic effects of IFN while exploiting IFNmediated antitumor immunity.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Engineering interferons and interleukins for cancer immunotherapy
    Holder, Patrick G.
    Lim, Shion A.
    Huang, Christine S.
    Sharma, Preeti
    Dagdas, Yavuz S.
    Bulutoglu, Beyza
    Sockolosky, Jonathan T.
    ADVANCED DRUG DELIVERY REVIEWS, 2022, 182
  • [22] Novel strategies for cancer immunotherapy: counter-immunoediting therapy
    Liu, Shaochuan
    Sun, Qian
    Ren, Xiubao
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [23] Cancer immunoediting and resistance to T cell-based immunotherapy
    Jake S. O’Donnell
    Michele W. L. Teng
    Mark J. Smyth
    Nature Reviews Clinical Oncology, 2019, 16 : 151 - 167
  • [24] Novel strategies for cancer immunotherapy: counter-immunoediting therapy
    Shaochuan Liu
    Qian Sun
    Xiubao Ren
    Journal of Hematology & Oncology, 16
  • [25] Cancer immunoediting and resistance to T cell-based immunotherapy
    O'Donnell, Jake S.
    Teng, Michele W. L.
    Smyth, Mark J.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (03) : 151 - 167
  • [26] DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and immunotherapy response
    Baldwin, Louise A.
    Bartonicek, Nenad
    Yang, Jessica
    Wu, Sunny Z.
    Deng, Niantao
    Roden, Daniel L.
    Chan, Chia-Ling
    Al-Eryani, Ghamdan
    Zanker, Damien J.
    Parker, Belinda S.
    Swarbrick, Alexander
    Junankar, Simon
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [27] Dna barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and in response to immunotherapy
    Baldwin, Louise A.
    Bartonicek, Nenad
    Yang, Jessica
    Wu, Sunny Z.
    Deng, Niantao
    Roden, Daniel
    Chan, Chia-Ling
    Al-Eryani, Ghamdan
    Zanker, Damien J.
    Parker, Belinda S.
    Swarbrick, Alexander
    Junankar, Simon
    CANCER RESEARCH, 2022, 82 (04)
  • [28] DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and immunotherapy response
    Louise A. Baldwin
    Nenad Bartonicek
    Jessica Yang
    Sunny Z. Wu
    Niantao Deng
    Daniel L. Roden
    Chia-Ling Chan
    Ghamdan Al-Eryani
    Damien J. Zanker
    Belinda S. Parker
    Alexander Swarbrick
    Simon Junankar
    Nature Communications, 13
  • [29] Sculpting tumor microenvironment with immune system: from immunometabolism to immunoediting
    Yu, Y. -R.
    Ho, P. -C.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2019, 197 (02): : 153 - 160
  • [30] Cancer immunoediting is associated with checkpoint inhibitor response
    Ring, S. S.
    Pop, O. T.
    Pozniak, J.
    Berner, F.
    Ali, Hasan O.
    Abdou, M. -T.
    Diem, S.
    Bomze, D.
    Niederer, R.
    Faesler, M.
    Landeloos, E.
    Rambow, F.
    Bervoets, G.
    Freiberger, S. N.
    Mayr, T.
    Muders, M.
    van den Broek, M.
    Bald, T.
    Landsberg, J.
    Dietrich, D.
    Mangana, J.
    Cozzio, A.
    Garbe, C.
    Dummer, R.
    Jochum, W.
    Levesque, M. P.
    Ludewig, B.
    Bechter, O.
    Marine, J. -C.
    Tuting, T.
    Holzel, M.
    Flatz, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 14 - 14